PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 70 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 Young Woman Considers Service Dog A Crucial Ally In Her Battle... July 20, 2020 New on NCI’s Websites for June 2022 June 10, 2022 How Some Brain Tumors Hijack the Mind to Grow June 21, 2023 Load more HOT NEWS 2021/22 in review: Charity looks to the future with ambitious new... The team of over 60 scientists investigating the age-old mystery of... Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... How to Stay Healthy After Cancer
